Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated autologous T cells
- Development stage
- Unknown
- Lead developer
- Cedars-Sinai
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Activated autologous T cells (ATC) is an experimental adoptive cell therapy being investigated by Dr. Jeremy Rudnick at Cedars-Sinai Medical Center for the treatment of recurrent glioblastoma. The therapy involves the ex vivo activation and expansion of a patient's own T lymphocytes, which are then re-infused intravenously. This specific protocol targets antigens associated with glioma cancer stem cells (GCSCs), a subpopulation of tumor cells believed to be responsible for tumor initiation, progression, and resistance to conventional treatments. The primary objective of the ongoing Phase I study (NCT04003649) is to evaluate the safety and tolerability of the treatment and to determine the maximum tolerated dose in patients with recurrent glioblastoma.
- Other names
- Activated T cellsATCAutologous activated T cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)Interleukin-13 receptor subunit alpha-2 peptide epitopes presented by HLA class I/IICD133/HLA-I (CD133 peptide epitopes presented by HLA class I)
Beyond the preview
Go deeper on activated autologous T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated autologous T cells.